ArticleOphthalmology. Glaucoma
The Effect of Medication Adherence on Intraocular Pressure and Glaucoma Progression.
Article in Ophthalmology. Glaucoma. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [Experiences of glaucoma patients : Evaluation of the survey conducted by the Federal Association Glaucoma Self-help and the DOG Glaucoma Section].Die Ophthalmologie · 2026Article
- Evidence architecture of glaucoma-related biomaterials reveals an uneven transition toward smart materials, additive manufacturing, and functional tissue engineering.Frontiers in bioengineering and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeLittle is known about how medication adherence is related to longitudinal structural and functional losses. Here, we investigate the associations between medication adherence with mean intraocular pressure (IOP) measurements, explore whether adherence predicts rates of change in mean deviation (MD) and retinal nerve fiber layer thickness (RNFLT), and identify factors associated with worse adherence using a large sample of glaucoma and glaucoma suspect eyes.
designA retrospective longitudinal cohort study.
participantsAdults with glaucoma or glaucoma suspect status in at least 1 eye, defined by ICD code H40. All eyes had a minimum of five visual field or OCT tests over time.
methodsProportion of days covered (PDC), defined as the proportion of days a patient has access to their medication over a given period using pharmacy refill data, was used to assess adherence. Multivariable linear mixed-effects models were used to investigate the relationship between PDC with mean IOP and rates of change in both MD and RNFLT. Similar models were employed to examine predictors of PDC.
main outcome measuresMean IOP, rates of change in MD, and RNFLT.
resultsA total of 13 670 eyes from 8163 patients were included with a median (interquartile range) PDC of 60 (40.9-77.5). Below the 60% adherence threshold (median), each 10% decrease in PDC was associated with higher mean IOP (β = 0.82 mmHg, P < 0.001), while the association showed a smaller effect size above the median (β = 0.37 mmHg, P < 0.001). Proportion of days covered was associated with -0.03 units/year faster rates of MD and RNFLT loss (P < 0.01). Predictors of worse PDC included female gender (β = -1.22%, P = 0.02; vs. males), Black race (β = -5.04%, P < 0.001; vs. White), worse baseline MD (β = -0.23%, P = 0.01; per 5 decibel decrease), lower baseline RNFLT (β = -0.17%, P = 0.03; per 10 μm thinner), using two eye drops (β = -6.37%, P < 0.001; vs. 1), and unilateral drop use (β = -8.85%, P < 0.001; vs. bilateral).
conclusionsLower adherence was associated with higher IOP, with a stronger effect seen at PDC values below the median, and accelerated glaucomatous damage, including faster rates of MD deterioration and increased RNFLT loss. Lower adherence was associated with female gender, Black race, greater baseline damage, greater number of drops, and unilateral drop use. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.